Literature DB >> 2880224

Which treatment for childhood acute lymphoblastic leukaemia in second remission?

A Butturini, G K Rivera, M M Bortin, R P Gale.   

Abstract

The best therapy for children with acute lymphoblastic leukaemia (ALL) who have an initial bone marrow relapse and subsequently achieve second remission is controversial. Some findings suggest that bone marrow transplantation (BMT) is better than chemotherapy whereas others do not. An analysis of 871 children treated by BMT or chemotherapy showed that outcome was correlated with risk factors at diagnosis and with length of first remission. BMT seemed superior in patients who relapsed within 18 months of first remission while on maintenance chemotherapy. BMT was not demonstrably superior in patients who relapsed more than 18 months after first remission. The choice of treatment in childhood ALL must be based on prognostic variables at diagnosis and on the circumstances of the relapse.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2880224     DOI: 10.1016/s0140-6736(87)90128-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia.

Authors:  G Henze; R Fengler; R Hartmann; R Dopfer; U Göbel; N Graf; H Jürgens; D Niethammer; J Ritter; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

Authors:  Richard H Ko; Lingyun Ji; Phillip Barnette; Bruce Bostrom; Raymond Hutchinson; Elizabeth Raetz; Nita L Seibel; Clare J Twist; Elena Eckroth; Richard Sposto; Paul S Gaynon; Mignon L Loh
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

Review 3.  An odyssey in search of a cure: the evolution of treatment of childhood acute lymphoblastic leukemia in the United Kingdom.

Authors:  V Saha; T Eden
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

4.  CXCL1, CXCL10 and CXCL12 Chemokines are Variously Expressed in Acute Myeloid Leukemia Patients Prior and Post Bone Marrow Transplantation.

Authors:  Bahar Yazdani; Gholamhossein Hassanshahi; Zahra Mousavi; Zahra Ahmadi; Hussein Khorramdelazad; Alireza Moradabadi; Mohamadreza Shafiepoor; Abbas Fatehi
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01

5.  Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?

Authors:  L Lennard; H A Davies; J S Lilleyman
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.